^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    NOUS-PEV

    i
    Associations

    News

    Trials
    Company:
    Nouscom
    Drug class:
    Immunostimulant
    Related drugs:
    Associations

    News

    Trials
    27d
    Nous-PEV: a Novel Immunotherapy for Lung Cancer and Melanoma (clinicaltrials.gov)
    P1, N=7, Terminated, Nouscom SRL | Phase classification: P1b --> P1 | N=34 --> 7 | Active, not recruiting --> Terminated; Terminated by Sponsor
    Phase classification • Enrollment change • Trial termination
    |
    EGFR (Epidermal growth factor receptor) • PD-L1 (Programmed death ligand 1) • ALK (Anaplastic lymphoma kinase) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS)
    |
    PD-L1 expression
    |
    Keytruda (pembrolizumab) • NOUS-PEV
    1year
    Phase I trial of viral vector based personalized vaccination elicits robust neoantigen specific antitumor T cell responses. (PubMed, Clin Cancer Res)
    These findings indicate the ability of NOUS-PEV to amplify and broaden the repertoire of tumor reactive T cells to empower a diverse, potent and durable antitumor immune response. Finally, a gene signature indicative for reduced presence of activated T cells together with very poor expression of the antigen processing machinery (APM) genes has been identified in pre-treatment biopsies as a potential biomarker of resistance to the treatment.
    P1 data • Journal • PD(L)-1 Biomarker • Viral vector
    |
    CD8 (cluster of differentiation 8) • CD4 (CD4 Molecule)
    |
    Keytruda (pembrolizumab) • NOUS-PEV
    2years
    Nous-PEV: a Novel Immunotherapy for Lung Cancer and Melanoma (clinicaltrials.gov)
    P1b, N=34, Active, not recruiting, Nouscom SRL | Recruiting --> Active, not recruiting
    Enrollment closed • Metastases
    |
    EGFR (Epidermal growth factor receptor) • PD-L1 (Programmed death ligand 1) • ALK (Anaplastic lymphoma kinase) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS)
    |
    PD-L1 expression
    |
    Keytruda (pembrolizumab) • NOUS-PEV
    over3years
    Nous-PEV: a Novel Immunotherapy for Lung Cancer and Melanoma (clinicaltrials.gov)
    P1b, N=34, Recruiting, Nouscom SRL
    Clinical • New P1 trial
    |
    EGFR (Epidermal growth factor receptor) • PD-L1 (Programmed death ligand 1) • ALK (Anaplastic lymphoma kinase) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS)
    |
    PD-L1 expression
    |
    Keytruda (pembrolizumab) • NOUS-PEV